Citadel Advisors’s ProKidney PROK Stock Holding History

Citadel Advisors’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-371,797	Closed	-$789K	–	13966
2025 Q4	$833K	Buy	371,797 +27,008	+8%	+$71K	﹤0.01%	7827
2025 Q3	$834K	Buy	+344,789	New	+$918K	﹤0.01%	7939
2025 Q1	–	Sell	-327	Closed	-$454	–	15345
2024 Q4	$553	Buy	+327	New	+$590	﹤0.01%	14307
2024 Q2	–	Sell	-6,096	Closed	-$16.4K	–	15141
2024 Q1	$10K	Sell	6,096 -8,520	-58%	-$12.5K	﹤0.01%	13476
2023 Q4	$26K	Buy	+14,616	New	+$31.3K	﹤0.01%	12389
2023 Q3	–	Sell	-900	Closed	-$10.1K	–	14920
2023 Q2	$10.1K	Buy	+900	New	+$9.58K	﹤0.01%	13222
2022 Q3	–	Sell	-627,066	Closed	-$6.24M	–	13380
2022 Q2	$6.24M	Sell	627,066 -516,263	-45%	-$5.1M	﹤0.01%	3403
2022 Q1	$11.3M	Buy	1,143,329 +1,023,148	+851%	+$10.1M	﹤0.01%	2757
2021 Q4	$1.19M	Buy	120,181 +3,055	+3%	+$30.2K	﹤0.01%	7520
2021 Q3	$1.15M	Sell	117,126 -708,635	-86%	-$6.98M	﹤0.01%	7797
2021 Q2	$8.37M	Buy	+825,761	New	+$8.35M	﹤0.01%	3397

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

AGP

Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's PROK Position: Q1 2026 in Review

Citadel Advisors sold out of ProKidney (PROK) in Q1 2026, closing a stake of 371,797 shares — an estimated $789K sold.

Citadel Advisors first reported a position in PROK in Q2 2021 and held it in 11 quarters. The position peaked at $11.3M in Q1 2022. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

Citadel Advisors reported no remaining ProKidney position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 371,797 ProKidney shares in Q1 2026, an estimated $789K.
Citadel Advisors first reported a position in ProKidney in Q2 2021 and held it in 11 quarters.
Citadel Advisors's ProKidney position peaked at $11.3M in Q1 2022.
71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.